More Potent Antiplatelet Agent Not Better for PAD

ACC Conference Reporter

AHA 2016 | NEW ORLEANS — The potent antiplatelet agent ticagrelor (Brilinta) didn't improve outcomes or reduce bleeding compared with clopidogrel (Plavix) for symptomatic peripheral arterial disease (PAD) patients, the double-blind EUCLID trial showed. Read More >>>

Keywords: AHA Annual Scientific Sessions, AHA16

< Back to Listings